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Abstract
Transformation by tyrosine kinase oncogenes in myeloid malignancies, including BCR-ABL in
chronic myeloid leukemia, FLT3ITD in acute myeloid leukemia (AML) or JAK2V617F in
myeloproliferative neoplasms (MPN), is associated with increased growth and cytoskeletal
abnormalities. Using targeted approaches against components of the superoxide-producing
NADPH-oxidases, including NOX2, NOX4 and the common p22phox subunit of NOX1-4,
myeloid cells were found to display reduced cell growth and spontaneous migration. Consistent
with a role of NOX as regulators of membrane proximal signaling events in non-phagocytic cells,
NOX2 and NOX4 were not involved in the excess production of intracellular reactive oxygen
species and did not significantly increase oxygen consumption. All NOX family members are
controlled in part through levels of the rate-limiting substrate NADPH, which was found to be
significantly elevated in tyrosine kinase oncogene transformed cells. Also, reduced
phosphorylation of the actin filament crosslinking protein MARCKS in response to suppression of
p22phox hints at a novel effector of NOX signaling. MARCKS was also found to be required for
increased migration. Overall, these data suggest a model whereby NOX links metabolic NADPH
production to cellular events that directly contribute to transformation.
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tIntroduction
Constitutive activation of tyrosine kinase oncogenes (TKOs) due to mutations is frequently
associated with myeloid leukemias and myeloproliferative disorders. For example, the BCR-
ABL oncogene is associated with enhanced proliferation and viability of myeloid cells in
chronic myelogenous leukemia (CML),1 the JAK2V617F point mutation is an activating
mutation in patients with myeloproliferative disorders including polycythemia vera,
essential thrombocythemia, idiopathic myelofibrosis, and myelodysplastic syndromes2 and
activating mutations of the FMS-like receptor tyrosine kinase 3 (FLT3), such as internal
tandem duplications (ITD), are frequently linked to acute myeloid leukemia (AML).3 Cells
transformed by these and other TKOs are associated with elevated levels of intracellular
reactive oxygen species (ROS), defined here specifically as superoxide radicals, hydrogen
peroxide and hydroxyl radicals.4-6 This effect of TKOs on ROS is not limited to these
specific oncogenes and can also be found in other cancers, such as through oncogenic forms
of the receptor tyrosine kinase MET in lung cancer7 or in normal cells in response to chronic
stimulation with growth factors.8 Even though it is appreciated that elevated ROS are found
in many different types of cancers, their exact contribution to disease initiation, maintenance
or progression is not well understood. In proliferating cells, increased ROS are required for
growth and viability.9
In metabolically active cells, mitochondria are a major source of ROS, mostly as a
byproduct of the electron transport chain10, but cellular processes, such as enzymatic
reactions involving cytoplasmic NADPH reductase and others, may also nonspecifically
contribute to the pool of ROS. The role of NADPH oxidases (NOX) in the excess
production of ROS and their function in myeloid leukemia cells is not well understood. In
contrast to mitochondria, the primary function of NOX is the production of superoxide
radicals from molecular oxygen.11 Vast amounts of ROS can be produced in phagocytic
cells for respiratory burst function but only small amounts may be required for the
modulation of signaling mechanisms. NOX are multi-subunit transmembrane enzymes and
their expression varies in different cell types.12 The family of human NOX proteins consists
of five members (NOX1 to 5) and two related dual oxidases (DUOX1 and 2). NOX1, 2 and
3 show a high degree of homology and require p40phox, p47phox and p67phox subunits and
activation by Rac. In addition, p22phox subunit is important for the stability and functioning
of NOX1 to 4.11,13,14 On the other hand, NOX5 (absent in mice) does not require p22phox.11
Our current study was designed to determine the role of NOX in various cellular processes
including ROS generation, cell growth and migration in hematologic malignancies
transformed by TKOs. Using patient derived myeloid cell lines dependent on activated
tyrosine kinases for transformation, including KU812 (BCR-ABL), HEL (JAK2V617F) and
Molm13 (FLT3ITD), the function of NOX proteins was determined. shRNA knockdown of
p22phox, NOX2 and NOX4 demonstrated that these proteins are crucial regulators of cell
growth and migration but may not be involved in the excess production of intracellular ROS
levels. NOX proteins can be regulated at different levels and we found that tyrosine kinase
oncoproteins were associated with increased amounts of the rate-limiting substrate NADPH.
NOX signaling may be mediated through MARCKS (Myristoylated alanine-rich C-kinase
substrate) phosphorylation at its regulatory site. Since NOX2 and NOX4 do not appear to be
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trequired for the excess production of ROS, the biological and biochemical effects are
expected to be through proximal effectors that depend on a localized increase in intracellular
ROS.
Materials and Methods
Cells
The murine BaF3 cells expressing BCR-ABL, JAK2V617F or FLT3ITD were maintained as
described.15 For ROS measurements cells were starved in medium without interleukin 3
(IL3). Human cell lines KU812 (Ph+; CML) and Molm13 (FLT3ITD+; AML) were grown
in RPMI 1640 (Mediatech, Manassas, VA) containing 10% fetal bovine serum (FBS; Lonza,
Walkersville, MD). HEL cells (JAK2V617F+; erythroleukemia) were grown in medium
containing sodium pyruvate (1mM; Invitrogen, Carlsbad, CA). In some experiments, cells
were treated with metabolic analogs, including 2-deoxyglucose (dose response or
4.5mg/mL, Sigma, St. Louis, MO) and 3-bromopyruvate (100μM, Sigma), the flavoprotein
inhibitor diphenyleneiodonium (DPI, 5μM, Sigma) or kinase inhibitors, including imatinib
(1μM; Novartis, Basel, Switzerland), Jak inhibitor (1μM; Calbiochem, Gibbstown, NJ), and
midostaurin (50nM; Novartis). 293T cells were grown in Dulbecco's Modified Eagle
Medium (DMEM; Mediatech) supplemented with 10% FBS.
Semi-quantitative real-time PCR
NOX and DUOX gene expression was measured by semi-quantitative real-time PCR using
specific primers (Invitrogen) (Supplementary Table 1) and the products confirmed by DNA
sequencing (not shown). Total RNA was extracted (RNeasy kit, Qiagen, Valencia, CA) to
synthesize cDNA (Taqman Reverse Transcription Reagents, Applied Biosystems, Foster
City, CA) for semi-quantitative real-time PCR (Power SYBR green PCR master mix) using
a 7500 Real-Time PCR System (both Applied Biosystems).
Targeted knockdown using lentiviral approaches
Knockdown of NOX2, NOX4 or p22phox was done using an shRNA method. Three different
constructs (RNAi Screening Facility, Dana-Farber Cancer Institute) were used (A-C) out of
a pool of up to five. Lentiviruses containing shRNA were generated by co-transfecting 293T
cells with viral packaging vectors, pMD2.GVSV-G and pCMVΔ8.91 (RNAi Screening
Facility) and shRNAs using the TransIT (Mirus, Madison, WI) reagent. Cells were infected
in the presence of polybrene (5μg/mL; Millipore, Temecula, CA) and selected in medium
containing puromycin (3μg/mL; Sigma). The efficiency of knockdown was confirmed by
semi-quantitative real-time PCR and immunoblotting.
Immunoblotting
Immunoblotting was performed as described previously.15 The antibodies used were as
follows: Polyclonal rabbit antibodies against NOX2 (Millipore), NOX4 (recognizes the 32
kDa isoform 4; Novus Biologicals, Littleton, CO), p22phox (Santa Cruz Biotechnology),
pMARCKS (phospho-Ser152/156; Cell Signaling, Danvers, MA), pERK1/2 (phospho-
Thr202/Tyr204; Cell Signaling) and pGSK3β (phospho-Ser9; Cell Signaling); monoclonal
rabbit antibodies against β1 integrin (EP1041Y; Abcam, Cambridge, MA) and pAkt
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t(C31E5E, phospho-Thr308; Cell Signaling); mouse monoclonal antibodies against β-actin
(AC-15; Sigma).
Isolation of membrane fractions
Knockdown of NOX2 was confirmed by immunoblotting of the proteins in the enriched
membrane fractions. Briefly, cells were incubated in hypotonic lysis buffer containing Tris
(10mM, pH 8.0; Invitrogen), EDTA (1mM; Sigma), Na3VO4 (1mM; Sigma), and protease
inhibitor cocktail (Complete; Roche Diagnostics) for 10 min and homogenized. Nuclei were
separated by centrifuging at 1500g for 5 min. Supernatant was separated and
ultracentrifuged at 100,000g for 1h at 4°C. The proteins in the membrane pellet were used
for immunoblotting.
Measurement of intracellular and extracellular ROS
The relative levels of intracellular ROS were measured using the redox-sensitive dye 2′,7′-
dichlorofluorescein diacetate (DCF-DA; Calbiochem, La Jolla, CA)8 or by MitoSOX Red
(Invitrogen) staining. Cells (1×106) were washed with PBS (Mediatech), incubated with
DCF-DA (20μM) for 5 min at 37°C or with MitoSOX Red (5μM) for 10 min at 37°C,
subsequently washed twice in PBS and analyzed on a FACSCanto II flow cytometer (BD
Biosciences, San Jose, CA). In control experiments, extracellular superoxide production was
measured using a chemiluminescence assay (Diogenes Cellular Luminescence Enhancement
System, National Diagnostics, Atlanta, GA). Cells (10×106) were washed twice with PBS
before treatment with 50 μM phorbol 12-myristate 13-acetate (PMA, Sigma) at 37°C for 10
min. Diogenes reagent was added and superoxide measured (Monolight 3010 luminometer,
Pharmingen, San Diego, CA) continuously for 100s to verify a linear increase in
luminescence.
Oxygen consumption
A Clark-type oxygen electrode connected to a Mitocell MT200A respirometer and a Model
782 oxygen meter (Strathkelvin Instruments, North Lanarkshire, Scotland) was used to
measure oxygen consumption. The amount of oxygen consumed was continuously recorded
for 30 min at 37°C in cells pretreated with tyrosine kinase inhibitors or in cells with p22phox
knockdown. The rate of oxygen consumption was compared to starved, untreated or control
shRNA transfected cells.
Migration assay
Migration of HEL and Molm13 cells with p22phox knockdown was measured using
Transwell inserts (8μm) (Corning Incorporated, Corning, NY). Matrigel invasion chambers
(8μm) (BD Biosciences) were used to measure migration of KU812 cells with p22phox
knockdown. The relative number of migrated cells in the bottom chamber was counted after
6-8 h and compared to control cells.
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Cellular NADPH levels (106 cells) were measured using an NADPH assay kit (Abcam)
according to the manufacturer's instructions without modifications and relative levels were
quantified on a SpectraMax 190 microplate reader (Molecular Dynamics, Sunnyvale, CA).
Targeted knockdown using siRNA
Knockdown of MARCKS was done using specific siRNA and compared to scrambled
siRNA (Santa Cruz Biotechnology Inc., Santa Cruz, CA). HEL cells were transfected with
siRNAs in 100 μL Nucleofector solution V (Amaxa, Gaithersburg, MD) according to the
manufacturer's instructions using the Nucleofector device. Expression of MARCKS was
analyzed by real-time PCR 24h after transfection.
Statistical analysis
For statistical comparison between groups, the Student's t-test was used. p values of less
than 0.05 were considered significant. Error bars represent SEM (standard error of the mean)
of at least three independent experiments.
Results
NOX proteins are expressed in cell lines transformed by oncogenic tyrosine kinases
Hematopoietic cells expressing TKOs associated with these diseases, including BCR-ABL,
JAK2V617F and FLT3ITD, have been found to display elevated levels of intracellular
ROS.4-6 Recently, NOX have been implicated in various cancers, however, their role in
hematologic malignancies is not well understood. Using patient-derived KU812 (BCR-
ABL), HEL (JAK2V617F) and Molm13 (FLT3ITD) cells, we determined the expression of
the various NOX components. Semi-quantitative real-time PCR detected expression of
NOX2, NOX4, and NOX5 as well as p22phox, p40phox, p47phox, and p67phox in these cells
(Figure 1A). The results also indicated that NOX4 and NOX5 were expressed with a Ct
value at least 3-fold higher compared to NOX2 (not shown). We did not observe expression
of NOX1, NOX3, DUOX1 and DUOX2 in these cells. Interestingly, murine BaF3 cells
expressing BCR-ABL, JAK2V617F and FLT3ITD only expressed NOX1, NOX2 and
NOX4 (data not shown). The gene for NOX5 is absent in the murine genome. NOX proteins
are dependent on reduced NADPH, which is oxidized for the production of superoxide
radicals and this process can be inhibited by diphenyleneiodonium (DPI). In initial
experiments, DPI (5μM) was found to strongly reduce ROS levels in KU812 (69.6±0.4%),
HEL (77.1±0.5%) and Molm13 (72.2±0.9%) cells (Suppl. Fig. 1). Nevertheless, this small
molecule drug was originally identified as an inhibitor of mitochondrial respiration, may
have additional effects on carbon metabolism and is now considered to be a flavoprotein
inhibitor.16 We therefore sought to determine the role of NOX proteins in ROS production
and transformation by using a specific genetic approach with lentiviral-based shRNA
knockdown. The expression of NOX2 and NOX4 was targeted since it is common to both
murine and human cells. In addition, p22phox which is required for stability and functioning
of NOX1 to 4 was stably knocked down, therefore also controlling for functional
redundancy between the NOX genes.11,13,14 The efficiency of knockdown using three
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tdifferent shRNA constructs was confirmed by real-time PCR (data not shown) and most
importantly, the efficient reduction in protein levels was confirmed by immunoblotting
(Figure 1B). Since KU812 and HEL cells are not respiratory burst competent,17 we
confirmed that NOX proteins were functionally silenced in Molm13 cells with p22phox
knockdown. Superoxide production in response to the respiratory burst activator PMA was
found to be reduced by 76.9% to 89.1%, using three different lentiviral constructs targeting
p22phox in these cells (Figure 1C).
Tyrosine kinase oncogenes increase oxygen consumption
Univalent reductions of molecular oxygen by stepwise electron transfer is required for the
production of various ROS, generating sequential intermediates starting with superoxide
radicals (O2•-), to hydrogen peroxide (H2O2) and to hydroxyl radicals (•OH). Thus, changes
in oxygen consumption are an indirect measurement of potential changes in ROS. In BaF3
cells transformed by TKOs, the oxygen consumption was significantly increased (BCR-
ABL: 182.1±14.8%; JAK2V617F: 210±15.8%; FLT3ITD: 125.7±6.8% increase) (Figure
2A). Consequently, in KU812, HEL and Molm13 cells, oxygen consumption was reduced in
a dose dependent manner in response to their respective tyrosine kinase inhibitors, including
imatinib (1μM; 70.6±6.5%), Jak inhibitor (2μM; 62.5±2.9%) and midostaurin (100nM;
57.3±2.5%) (Figure 2B). Oxygen consumption was also measured in KU812, HEL and
Molm13 cells with p22phox knockdown. We did not observe significant difference in oxygen
consumption between control cells and cells with targeted knockdown, suggesting that NOX
do not consume a significant amount of molecular oxygen (Figure 2C). We had previously
demonstrated that mitochondria are a significant source of intracellular ROS in cells
transformed by BCR-ABL, using electron transport chain inhibitors to block mitochondrial
ROS production18 and similar data were obtained in cell line models used here (not shown).
Mitochondrial ROS are increased in tyrosine kinase oncogene-transformed cells
Next, we measured intracellular levels of ROS directly using redox-sensitive fluorochromes.
In murine BaF3 cells, intracellular levels of ROS are elevated in the presence of BCR-ABL
(129.4±21.9%), JAK2V617F (145.7±20.7%) and FLT3ITD (193.1±20.6%), when compared
to the parental cell line (Figure 3A). Also, in KU812, HEL and Molm13 cells, the presence
of their respective kinase inhibitor led to a reduction in ROS levels, including imatinib
(1μM; 29.1±2.6%), Jak inhibitor (1μM; 33.2±1.9%) and midostaurin (50nM; 23.0±1.1%)
(Figure 3B). These data confirm previous findings suggesting that TKOs are sufficient and
required for the increase in ROS4,19. Our previous data using the hexokinase inhibitor 2-
deoxyglucose suggested that elevated ROS in BCR-ABL transformed cells are dependent, at
least in part, on cellular glucose (carbon) metabolism18 and similar results were found in
TKO transformed BaF3 cells as well as KU812, HEL and Molm13 cells (Suppl. Fig. 2). In
order to further confirm the role of mitochondria in ROS production, we also used the
mitochondrial redox sensitive fluorochrome MitoSOX Red. Consistent with the above data,
KU812, HEL and Molm13 cells, displayed reduced MitoSOX Red fluorescence in response
to tyrosine kinase inhibitors, including imatinib (1μM; 38.9±2.5%), Jak inhibitor (1μM;
31.4±1.8%) and midostaurin (50nM; 41.9±1.1%), respectively (Figure 3C). In additional
control experiments, we confirmed that elevated ROS indeed require an active electron
transport chain using CML, AML and polycythemia vera patient specimens (not shown).
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tNext, using DCF-DA staining, the amount of intracellular ROS was measured in control and
NOX-targeted shRNA containing cells. Consistent with a lack in change of oxygen
consumption in p22phox knockdown cells, there was no significant reduction in ROS levels
in cells with NOX2, NOX4 and p22phox knockdown compared to control cells (Figure 3D).
In order to evaluate clonal effects as a result of stable integration and selection for cells with
targeted knockdown, transient knockdown with the p22phox construct was also performed.
Also in these experiments, we did not observe a significant reduction in intracellular ROS
(not shown). The data imply that NOX proteins do not significantly participate in the excess
production of intracellular ROS in TKO transformed cells.
NOX proteins regulate growth and migration
Finally, the effect of the knockdown on cell growth and migration using cells with p22phox
knockdown was tested. We found significant reduction in cell growth (72 h culture) in
KU812 (17.1-31.6%, p<0.05), HEL (27.9-50.9%, p<0.05) and Molm13 (32.0-54.0%,
p<0.05) cells compared to control shRNA-transfected cells (Figure 4A). Significant changes
in viability were not detected under these experimental conditions (not shown). Similar to
cell growth, a drastic reduction in migration compared to control cells was observed in
KU812 (74.3-87.6%, p<0.05), HEL (47.1-67.6%, p<0.05) and Molm13 (51.0-75.6%,
p<0.05) cells (Figure 4B). These data did not indicate whether growth and migration were
regulated through NOX2 or NOX4. Using the same approach, we first measured potential
changes in cell growth in single population with NOX2 and NOX4 knockdown. Consistent
with p22phox knockdown, NOX2- and NOX4-targeted approaches in the cell lines tested led
to a significant reduction of growth by 34.2-52.8% and 41.2-56.5% (p<0.05), respectively
(Figure 4C). We also found that in these cells both NOX2 (55.3-86.1% reduction, p<0.05)
and NOX4 (56.5-85.6% reduction, p<0.05) were required for optimal migration (Figure 4D).
We did not detect a significant change in cell growth during the migration assays.
Interestingly, BaF3 cells that are transformed by the TKOs tested are fully dependent on the
transforming tyrosine kinase activity for growth and spontaneous migration, in contrast to
parental BaF3 cells, which do not proliferate or migrate under identical experimental
conditions (not shown). These data suggest that NOX proteins play an important role in
growth and migration of hematopoietic cells transformed by TKOs.
Tyrosine kinase oncogenes increase NADPH levels but not NOX expression
The functional regulation of NOX proteins in cells has been well characterized and might
depend in part on the cellular context and the NOX isoforms expressed. NOX2 and NOX4
activities can be both regulated through changes in expression and through the availability of
their main substrate NADPH. The regulation of NOX2 is more complex than NOX4 and
may be influenced by additional factors and signaling molecules, which are not measured
here. Initially, we looked for changes in the expression of NOX components in KU812, HEL
and Molm13 in response to tyrosine kinase inhibition (Figure 5A). We did not observe a
significant reduction in NOX components, suggesting that the associated tyrosine kinase
oncoproteins are not likely to regulate NOX through elevated levels. Moreover, some NOX
components were even found to be increased, suggesting that the oncogenic tyrosine kinase
activities lead to a reduction in the levels of some components, depending on the cellular
background. Next, cellular NADPH levels were measured, which are in particular critical for
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tthe regulation of the constitutively active NOX420 but are also rate-limiting for NOX2.21,22
The cellular NADPH levels were significantly increased in BaF3 cells transformed by
TKOs, (BCR-ABL: 427.9±54.2%; JAK2V617F: 453.1±70.9%; FLT3ITD: 743.5±108.7%
increase) (Figure 5B). Similarly, in KU812, HEL and Molm13 cells, NADPH levels were
reduced in response to imatinib (1μM; 70.6±0.8%), Jak inhibitor (1μM; 62.5±6.1%) and
midostaurin (50nM; 57.3±5.5%), respectively (Figure 5C). Thus, changes in NADPH levels
may constitute an important mechanism for the regulation of NOX proteins by TKOs.
Additional experiments would be required to determine whether the observed changes in
NADPH levels are sufficient to effectively alter NOX activities and cause changes in
biological phenotypes.
p22phox is required for phosphorylation of MARCKS, a regulator of migration
In an attempt to identify signaling mechanisms regulated through NOX, we looked at
proteins known to be involved in the regulation of cytoskeletal reorganization in cells with
p22phox knockdown. We found that phosphorylation of the actin cross-linking protein
MARCKS at the regulatory Ser152/156 was specifically reduced in KU812, HEL and
Molm13 with p22phox knockdown (Figure 6A, top panel). As a negative control, we did not
detect changed phosphorylation at the activation sites of AKT (Thr308), ERK1/2 (Thr202/
Tyr204) or GSK3β (Ser9) (Figure 6A, bottom panels). To test whether MARCKS would be
required for migration in transformed cells, we knocked down expression of this protein
with siRNA pools targeting MARCKS and compared them to non-targeting siRNA. HEL
cells were used due to their high degree of transfectability. Initially, knockdown of
MARCKS was confirmed by real-time PCR and led to a 55.0±3.0% (n=3; p<0.05) reduction
in expression levels compared to control transfected cells (Figure 6B, left panel). Consistent
with the above data, knockdown of MARCKS also led to a 35.2 ±5.7% (n=3; p<0.05)
reduction in migration of HEL cells (Figure 6B, right panel). Similar data were obtained in
KU812 cells with MARCKS knockdown (not shown). Molm13 cells, however, were found
to be difficult to transfect. In order to confirm the regulation of MARCKS phosphorylation,
we treated HEL cells with the flavoprotein inhibitor DPI, which is expected to block NOX
activity (Figure 6C), as well as an inhibitor of the oncogenic JAK2 kinase (Figure 6D). As
expected, treatment with both inhibitors significantly reduced migration (DPI, 47.7%
reduction; Jak inhibitor, 35.3% reduction) as well as MARCKS phosphorylation. Overall,
these data suggest an important role for NOX in MARCKS phosphorylation and a
requirement for this protein in cell migration. Future experiments would be necessary to
define a link between MARCKS phosphorylation and disease development.
Discussion
ROS are important signaling intermediates that participate in the regulation of different
biological activities, including cell signaling, growth, angiogenesis and differentiation, but
ROS can also be involved in processes that are detrimental to normal growth, such as
apoptosis and DNA damage.9 In phagocytic cells the role of superoxide-producing NOX
proteins has been well established as crucial effectors of host defense mechanisms.
Mutations that lead to loss of NOX function result in the impaired ability of phagocytic cells
to defend against pathogens.23 The expression of NOX in non-phagocytic cells would imply
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tadditional functions and their role in myeloid neoplasms or other malignancies is just
beginning to emerge. Our experiments in cells with targeted knockdown of NOX2, NOX4
and p22phox indicate that these proteins are not significantly involved in the excess
production of ROS. Consistent with our data, Naughton et al. did not observe changes in
ROS in response to targeting NOX2 using murine BaF3 cells, but found NOX4 to be
required for BCR-ABL induced ROS and growth.24 However, NOX4 knockdown data also
demonstrated that ROS were still reduced when no changes in NOX4 protein levels were
observed at a later time point. In the absence of additional off target effects, this would
imply that subliminal changes in NOX4 are sufficient to effect oxidative stress. Our data
using three patient derived cell lines and p22phox as well as NOX4 knockdown, do not
support a role of NOX4 in the regulation of the excess production of ROS in human models.
It has been hypothesized that small amounts of ROS produced by NOX proteins may
regulate membrane proximal signaling events through redox-sensitive proteins in a variety
of cells.25 Woo et al. have also recently demonstrated that inactivation of detoxifying
peroxiredoxins in proximity to the membrane may restrict elevated ROS to the site of
production26, thus conveying specificity to this process without significantly increasing
intracellular ROS.
We observed significant growth reduction in KU812, HEL and Molm13 cells with p22phox,
NOX2 and NOX4 knockdown. NOX activity has previously been shown to be involved in
transformation, such as by overexpression of NOX1 in Ras transformed NIH3T3 fibroblasts,
causing increased cell growth and tumor formation in athymic mice.27 In pancreatic
adenocarcinoma, NOX4 showed a prosurvival role and knockdown resulted in apoptosis,
likely through AKT and apoptosis signal-regulating kinase 1 dependent mechanisms.28
Similarly, inhibition of NOX4 was also shown to suppress cell growth in melanoma cells
associated with partial G2-M cell cycle arrest.29 In addition to growth, our data also
suggested that NOX proteins are required for migration. Interestingly, we also found in data
not shown that inducible expression of active Rac (a component of the functional NOX2
complex) can regulate migration independent of excess production of ROS. Also, NOX can
show specific subcellular localization, such as membrane ruffles, lipid rafts, and
lamellipodia, leading to localized production of ROS that is likely to be required for cell-
matrix adhesions, cytoskeletal reorganization and cell migration.25
The primary targets of NOX-produced superoxide are not well characterized and may
include Rho family GTPases, protein tyrosine phosphatases or other proteins with redox-
sensitive cysteines.9 Our data demonstrate that knockdown of p22phox leads to reduced
phosphorylation of MARCKS in transformed cells. Also, MARCKS phosphorylation
required the active JAK2V617F kinase in HEL cells, suggesting a link between the
transforming kinase activity and NOX function. MARCKS was originally described as
myristoylated protein kinase C substrate. Phosphorylation of MARCKS is thought to disrupt
its interaction with acidic phospholipids, resulting in translocation to the actin cytoskeleton,
where it regulates actin function.30 Cells containing oncogenic tyrosine kinases are already
associated with spontaneous migration but the regulatory mechanisms are not well
understood.31 Whereas MARCKS is shown here to be a crucial regulator of this biological
effect, the potential role of MARCKS kinases, including protein kinase C isoforms, and the
redox mechanisms involved are not known. Preliminary data suggest that knockdown of
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tp22phox does not affect global activation of PKC isoforms (not shown) and it is therefore
likely that p22phox specifically targets individual kinases or phosphatases to regulate the
phosphorylation of MARCKS. Our data do not exclude a potential role of MARCKS in cell
growth but suggest that there may be different molecules involved that mediate a growth
advantage through NOX signaling pathways.
Growth and migration in cells transformed by TKOs depends on their active kinase activity
but it is not known how this is linked to NOX. Our data suggest that in the leukemic cell
lines tested that all NOX2 and NOX4 components are readily expressed and that this
expression does not depend on the oncogenic tyrosine kinase activity. NOX2 and NOX4 can
be regulated at different levels. For example, NOX2 requires active RAC, which has already
been associated with transformation by BCR-ABL.32 In contrast, NOX4 is constitutively
active and may be regulated in part through changes in its expression levels. Our data hint at
a potential regulation of NOX activities at the substrate level. NOX activity depends on the
presence of molecular oxygen and NADPH, which is the rate-limiting substrate for the
generation for superoxide, in particular for NOX4.20 We show that the relative levels of
NADPH in cells transformed by TKOs are elevated. Consequently, treatment with tyrosine
kinase inhibitors limits the availability of the major NOX substrate NADPH. There are
multiple sources of NADPH in the cell, but a major mechanism includes the catabolic
pentose phosphate pathway. Further characterization of changes in this and related catabolic
pathways in myeloid malignancies will provide a better understanding of the regulation of
NOX.
Our previous data suggested that glucose metabolism and mitochondrial ROS are important
for cell growth and survival in BCR-ABL transformed cells.4,18 Here we expand this finding
and suggest that the superoxide-producing NOX are important regulators of migration in
myeloid cells transformed by TKOs. It is not known whether this phenotype is specific for
these diseases and it would be interesting to see whether cells transformed by other
mechanisms or different types of cancer display a similar dependency on NOX for increased
migration. NOX effectors are expected to be specifically regulated through NOX-induced
ROS for the regulation of processes such as invasion and metastasis. Therefore, NOX and
downstream effectors would make ideal drug targets and blocking NOX mediated biological
functions could have beneficial effects in leukemia therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Expression and targeting of NOX proteins in cells transformed by tyrosine kinase
oncogenes
A-B. Patient derived KU812, HEL and Molm13 cells were used to determine the expression
of NOX proteins and their functional components. A. Gene expression of NOX2, NOX4,
NOX5, p22phox, p40phox, p47phox, p67phox and actin was determined by RT-PCR. B.
Cellular expression of NOX2, NOX4, and p22phox proteins was determined in response to
targeted knockdown with specific or control shRNA, as indicated. C. Superoxide production
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tin response to PMA (50 μM) treatment was measured using a chemiluminescence method in
Molm13 cells containing control shRNA or p22phox-targeting shRNA (n=3, *p<0.05).
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tFigure 2. Oxygen consumption in cells transformed by tyrosine kinase oncogenes
A Clarke-type electrode and temperature-controlled chamber were used to measure cellular
oxygen consumption. A. BaF3 cells expressing either BCR-ABL, JAK2V617F or FLT3ITD
were compared to the parental cell line. B-C. KU812, HEL and Molm13 cells were treated
with tyrosine kinase inhibitors (B) or cells with p22phox knockdown were used (C). (n=3,
*p<0.05).
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tFigure 3. ROS in cells transformed by tyrosine kinase oncogenes
Intracellular ROS levels were measured by DCF-DA (A, B, D) or MitoSox (C) staining in
tyrosine kinase transformed cells or in response to targeted approaches. A. BaF3 cells
expressing either BCR-ABL, JAK2V617F or FLT3ITD were compared to the parental cell
line (left panel). B-D. KU812 (BCR-ABL), HEL (JAK2V617F) and Molm13 (FLT3ITD)
cells were compared to kinase inhibitor treated cells (18h), as indicated (B-C) or control
cells were compared to cells with NOX2, NOX4 and p22phox knockdown (D). (n=3,
*p<0.05).
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tFigure 4. p22phox, NOX2 and NOX4 are required for optimal growth and migration
KU812, HEL and Molm13 cells were used to determine the biological consequences of
p22phox, NOX2 and NOX4 knockdown. Growth (A, C) and relative migration (B, D) were
determined in KU812, HEL and Molm13 cells with p22phox knockdown (A-B) and NOX2
or NOX4 knockdown (C-D) as well as in control cells (n=3, *p<0.05).
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tFigure 5. Tyrosine kinase oncogenes increase NADPH levels but not NOX expression
A. Changes in gene expression of NOX and their components in response to imatinib (1μM;
●) in KU812 cells, Jak inhibitor (1μM; ◆) in HEL cells and midostaurin (50nM; ▲)) in
Molm13 cells were determined by real-time PCR relative to their respective p-values
(volcano plot). Open symbols indicate changes in expression of Pim1. The horizontal dashed
line indicates the p=0.005 significance level and the vertical dotted lines indicate 3-fold
changes. B-C. NADPH levels were measured in whole cell extracts. BaF3 cells expressing
BCR-ABL, JAK2V617F and FLT3ITD were compared to parental BaF3 cells (B).
Untreated KU812, HEL and Molm13 cells were compared to cells treated with imatinib
(1μM), Jak inhibitor (1μM) and midostaurin (50nM), respectively (C).
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tFigure 6. Functional MARCKS expression is required for migration
A. KU812, HEL and Molm13 cells with p22phox knockdown were used to determine
phosphorylation of MARCKS, Akt, ERK1/2, or GSK3β and compared to control shRNA-
expressing cells. B. HEL cells were transfected with either control siRNA or MARCKS-
specific siRNA. Relative expression (left panel) and migration (right panel) were determined
24h after transfection. C-D. HEL cells were left untreated or treated for 6h with DPI (5μM)
(C) or for 18h with Jak inhibitor (1μM) (D) and relative migration (top) or MARCKS
phosphorylation (bottom) were determined. (n=3, *p<0.05).
Reddy et al. Page 19
Leukemia. Author manuscript; available in PMC 2014 July 02.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t